摘要
目的评价非布司他对慢性肾衰竭合并高尿酸血症患者治疗的有效性及安全性。方法 40例轻中度慢性肾衰竭合并高尿酸血症患者随机分为非布司他治疗组及别嘌呤醇治疗组各20例,观察二组患者治疗前及治疗8周后的相关临床指标变化,记录症状和体征。结果非布司他及别嘌呤醇治疗后患者血尿酸水平均明显下降,非布司他组疗效优于别嘌呤醇组(P<0.05)且不良反应轻微。结论非布司他对慢性肾衰竭合并高尿酸血症患者治疗有显著疗效且不良反应少。
Objective To evaluate the efficacy and safety of Febuxostat in the treatment of patients with chronic renal failure complicated with hyperuricemia.Methods A total of 40 patients with chronic renal failure complicating hyperuricemia were randomly divided into Febuxostat group and Allopurinol group,with 20 cases in each group.At the end of 8 weeks,the clinical index were detected,and the symptoms and physical signs were recorded.Results After treatment,the levels of Uric acid were significantly lower than those before the treatment,and the efficacy of Febuxostat was superior to Allopurinol（P〈0.05）,the advent reactions were mild.Conclusion Febuxostat is a safe and effective drug for the patients with chronic renal failure complicated with hyperuricemia.
出处
《中国煤炭工业医学杂志》
2015年第12期2042-2044,共3页
Chinese Journal of Coal Industry Medicine
